Article first published online: 6 APR 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 50, Issue 2, pages 400–406, August 2009
How to Cite
Lucey, M. R., Schaubel, D. E., Guidinger, M. K., Tome, S. and Merion, R. M. (2009), Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology, 50: 400–406. doi: 10.1002/hep.23007
Presented in part at the 2008 American Transplant Congress in Toronto, Ontario, Canada.
The views expressed herein are those of the authors and not necessarily those of the U.S. Government.
Potential conflicts of interest: Dr. Lucey is a consultant for Astellas. He also received grants from Novartis, Human Genome Sciences, Vertex, Bristol-Myers Squibb, Roche, and Schering-Plough.
- Issue published online: 29 JUL 2009
- Article first published online: 6 APR 2009
- Accepted manuscript online: 6 APR 2009 12:00AM EST
- Manuscript Accepted: 25 MAR 2009
- Manuscript Received: 8 OCT 2008
- National Institutes of Health Grant. Grant Number: R01 DK-70869
- The Scientific Registry of Transplant Recipients (SRTR). Grant Number: 234-2005-37009C
- U.S. Health Resources and Services Administration (HRSA)
- U.S. Department of Health and Human Services
- HRSA's SRTR project officer
- The HRSA
- Public Benefit and Service Program provisions. Grant Numbers: 45 CFR 46.101(b)(5), HRSA Circular 03
Disease-specific analysis of liver transplant survival benefit, which encompasses both pre- and posttransplant events, has not been reported. Therefore, we evaluated the effect of alcoholic liver disease (ALD) and hepatitis C virus (HCV) infection on waiting list mortality, posttransplant mortality, and the survival benefit of deceased donor liver transplantation using United States data from the Scientific Registry of Transplant Recipients on 38,899 adults placed on the transplant waiting list between September 2001 and December 2006. Subjects were classified according to the presence/absence of HCV and ALD. Cox regression was used to estimate waiting list mortality and posttransplant mortality separately. Survival benefit was assessed using sequential stratification. Overall, the presence of HCV significantly increased waiting list mortality, with a covariate-adjusted hazard ratio (HR) for HCV-positive (HCV+) compared with HCV-negative (HCV−) HR = 1.19 (P = 0.0001). The impact of HCV+ was significantly more pronounced (P = 0.001) among ALD-positive (ALD+) patients (HR = 1.36; P < 0.0001), but was still significant among ALD-negative (ALD−) patients (HR = 1.11; P = 0.02). The contrast between ALD+ and ALD− waiting list mortality was significant only among HCV+ patients (HR = 1.14; P = 0.006). Posttransplant mortality was significantly increased among HCV+ (versus HCV−) patients (HR = 1.26; P = 0.0009), but not among ALD+ (versus ALD−) patients. Survival benefit of transplantation was significantly decreased among HCV+ compared with HCV− recipients with model for end-stage liver disease (MELD) scores 9-29, but was significantly increased at MELD ≥30. ALD did not influence the survival benefit of transplantation at any MELD score. Conclusion: Except in patients with very low or very high MELD scores, HCV status has a significant negative impact on the survival benefit of liver transplantation. In contrast, the presence of ALD does not influence liver transplant survival benefit. (HEPATOLOGY 2009.)